Ovarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer
type overall in women. Ovarian cancer often presents genome instability, with almost half of …

Management of small cell lung cancer (SCLC) has not changed over the last decades. In
more recent years, alterations of DNA repair machinery and other molecular pathways have …

Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus
carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung …

Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on
histology, there are two major subtypes: Non-small cell lung cancer (NSCLC)(the more …

Progress in the treatment of small cell lung cancer (SCLC) has been modest over the past
decades until the advent of immune checkpoint inhibitors, which have redefined the …

Patient mortality rates have remained stubbornly high for the past decades in small cell lung
cancer (SCLC) because of having no standard targeted therapies with confirmed …

Simple Summary Small-cell lung cancer carries a dismal prognosis with few long-term
treatment options. The enzyme poly-(ADP)-ribose polymerase (PARP), which functions to …

Small cell lung cancer (SCLC) is treated as a monolithic disease despite the evident intra-
and intertumoral heterogeneity. Non-specific DNA-damaging agents have remained the first …

Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung
cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite …

Immune checkpoint inhibitors (ICIs) have brought new hope for the treatment of patients with
small cell lung cancer (SCLC) over the past decades. However, the overall response rate is …